New drug GI-108 targets Hard-to-Treat cancers in early trial
NCT ID NCT07172802
First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors (cancers that have spread). The drug is designed to help the immune system fight cancer. The trial has two parts: first, finding a safe dose, and then seeing if it shrinks tumors. About 76 adults with certain cancers (like lung, head and neck, pancreatic, or kidney cancer) will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
Contact Email: •••••@•••••
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, 03722, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.